Remove Big Data Remove Clinical Research Remove Medicine Remove Research
article thumbnail

Recognizing the Real People Behind the Big Data and Artificial Intelligence in Clinical Research

ACRP blog

If you hadn’t already noticed, the clinical research enterprise has well and truly entered the era of “big data,” artificial intelligence (AI), and machine learning. Undoubtedly, the expectations for precision medicine are high,” Olsen adds.

article thumbnail

AI, big data and deep real-world evidence – the challenges and opportunities

pharmaphorum

Real-world evidence (RWE) is emerging as an important area of research to reveal, in real time, new insights and innovations and is accelerating the development of new and innovative therapies and treatments to improve patient outcomes. The webinar will also cover: The challenges of RWE research and how they are being overcome.

Big Data 110
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

August 16, 2023: In This Friday’s PCT Grand Rounds, the Draft Revision of the ICH Good Clinical Practice Guideline

Rethinking Clinical Trials

Landry is a professor of medicine and epidemiology at Oxford Population Health and deputy director of the University of Oxford’s Big Data Institute. ElZarrad is the director of the Office of Medical Policy in the FDA’s Center for Drug Evaluation and Research. Join the online meeting.

article thumbnail

The future of AI drug discovery & development in immunology and GPCR research

pharmaphorum

Alphabet subsidiary and precision health company Verily recently announced a breakthrough in its AI drug discovery GPCR research collaboration with Sosei Heptares. The companies hope that in the year to come those data targets will be entered for validation, hit generation, and lead selection.

article thumbnail

Technology Trends and Collaborations are Ushering in a New Era of ‘Pharmaceutical Intelligence’

ACRP blog

Through these collaborations, advanced technologies tied to AI and big data are being employed to develop personalized and targeted medicines, ultimately leading to more effective treatments for diseases like cancer and immune deficiencies,” Lyons notes.

article thumbnail

Synthetic control arms in clinical trials: Making it happen

pharmaphorum

Attendees will learn more about how an SCA was used at the design and execution phases in a recent study of new treatments for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) and will also receive an eBook ‘How to harness the potential of AI and real-world data for clinical research’. About the panel.

article thumbnail

EMA pilot will see if clinical trial data should be digested ‘raw’

pharmaphorum

Currently, the EMA’s human medicines committee (CHMP) carries out its assessment of new medicines or post-marketing label extensions using data from clinical summaries and information reported in clinical study reports (CSRs).